Merrill Lynch rates Amgen a buy

Amgen Inc. was rated a buy with a price target of $104 by Merrill Lynch analyst Eric Ende, who said a patent issued to Roche could infringe on an Amgen patent. This weakness is viewed as a buying opportunity, Merrill Lynch said. Shares of the Thousand Oaks, Calif.-based biotechnology company were up $0.47, or 0.62%, at $75.87 on volume of 8,317,150 shares versus the three-month running average of 10,038,800 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.